John Reneau

12PUBLICATIONS
58CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 25, 2026
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Feb 04, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Zachary J Arnold, Jordan Lundberg, Tracy Wiczer

|Jul 01, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.

John Sharp, Qiuhong Zhao, Timothy J Voorhees

|Jan 02, 2024
GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.

Xiangrong Geng, Chenguang Wang, Suhaib Abdelrahman

|Dec 14, 2023
Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.

Zachary Braunstein, Allyson Waller, Emily Dotson

|Mar 27, 2023
Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas.

Xin Gao, Nermin Kady, Chenguang Wang

Pageof 2

Frequent Collaborators

4 joint publications

Ryan A Wilcox

3 joint publications

Carlos Murga-Zamalloa

3 joint publications

Zachary Braunstein

3 joint publications

Chenguang Wang